Wall Street analyst estimates for Immutep Limited (IMMP): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 4 |
| Avg rating (1-5) | 0.50 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-25 | $-0.06 | ||
| 2026-08-30 | $-0.17 | $-0.03 | -549.0% |
| 2026-02-24 | $-0.22 | $-0.20 | -9.9% |
| 2025-08-28 | $-0.20 | $-0.19 | -5.7% |
| 2025-02-26 | $-0.10 | $-0.14 | +29.2% |
| 2024-08-29 | $-0.12 | $-0.13 | +3.1% |
| 2024-04-29 | $-0.12 | $-0.12 | +3.4% |
| 2024-02-27 | $-0.12 | $-0.13 | +13.4% |
Valuation Ratios
| Price / Book | 1.03 |
| EV / EBITDA | -0.26 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.2M | $2.6M | $139782 | $7.5M | $3.9M | $170369 | $3.5M | $3.8M | $5.0M | $14.2M |
| Cost of Revenue | $1.7M | $10.0M | $16.6M | $22.5M | $17.2M | $2.1M | $2.1M | $41.5M | $61.4M | $2.4M |
| Gross Profit | $2.5M | -$7.4M | -$16.5M | -$15.0M | -$13.4M | -$1.9M | $1.4M | -$37.7M | -$56.4M | $11.8M |
| Research & Development | $7.5M | $10.0M | $16.6M | $20.4M | $17.2M | $31.3M | $28.8M | $41.5M | $61.4M | $75.0M |
| Selling, General & Admin | $4.3M | $7.2M | $6.1M | $6.3M | $6.3M | $7.2M | $14.1M | $8.9M | $8.6M | $18.9M |
| Operating Expenses | $9.5M | $14.8M | $19.1M | $22.6M | $18.3M | $32.5M | $44.9M | $50.4M | $70.1M | $93.9M |
| Operating Income | -$9.4M | -$11.7M | -$20.4M | -$16.0M | -$31.7M | -$33.9M | -$77.7M | -$88.1M | -$126.4M | -$82.0M |
| EBITDA | -$8.4M | -$10.4M | -$16.5M | -$11.4M | -$17.8M | -$31.9M | -$39.6M | -$44.5M | -$62.9M | -$79.6M |
| Interest Expense | 0 | 0 | 0 | $10457 | $9825 | $92430 | $20401 | $30594 | 0 | $66411 |
| Pre-tax Income | -$10.1M | -$12.7M | -$18.3M | -$13.5M | -$29.9M | -$32.2M | -$39.9M | -$42.7M | -$61.4M | -$77.6M |
| Income Tax | -$737387 | $1676 | -$2.1M | $37 | $33 | $34 | 0 | 0 | 0 | 0 |
| Net Income | -$9.4M | -$12.7M | -$16.3M | -$13.5M | -$29.9M | -$32.2M | -$39.9M | -$42.7M | -$61.4M | -$77.6M |
| EPS | $-0.44 | $-0.48 | $-0.47 | $-0.33 | $-0.49 | $-0.37 | $-0.44 | $-0.36 | $-0.42 | $-0.53 |
| EPS (Diluted) | $-0.44 | $-0.48 | $-0.47 | $-0.33 | $-0.49 | $-0.37 | $-0.44 | $-0.36 | $-0.42 | $-0.53 |
| Shares Outstanding (Diluted) | $42.7M | $42.7M | $42.7M | $40.7M | $60.4M | $86.2M | $90.1M | $120.1M | $145.6M | $147.2M |
Price
| Price | $0.33 |
| Market Cap | $48M |
| Exchange | NASDAQ |
| Country | AU |
Related companies: ACHV · ALLO · CABA · CADL · CAPR · EDIT · MREO
Explore sector: Healthcare · Biotechnology
More sections of IMMP: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks